Table 1. Demographics of patients with KD who underwent percutaneous coronary intervention

Patient	Sex	KD onset (years)	Age at intervention (years)	Aneurysm locations	Aneurysm diameters (mm)	Aneurysm types	Medications
1	M	4	40.6	LAD	10	Giant	DAPT
2	M	2.4	11.4	LAD, RCA	LAD 5.9	Fusiform	DAPT
3	M	3.7	21.2	LAD, RCA	LAD 7.7 Proximal RCA 10. Mid RCA 8.7	Giant	Warfarin, aspirin
4	M	6.0	7.9	RCA, LCx	RCA 7.4 LCx 5.5	Fusiform Saccular	Aspirin
5	F	1.7	14.6	LAD, RCA, LCx	Not available	Giant	Warfarin, Aspirin
6	M	Unknown	18.6	LMCA, RCA	LMCA 5.8 RCA 8.5	Fusiform Giant	Aspirin
7	M	5.7	10.0	RCA	5.2	Fusiform	DAPT
			17.6
8	M	2.0	5.2	RCA LAD	RCA 8 LAD 3.9	Giant Fusiform	DAPT
9	M	4.1	5.9	LMCA-LAD RCA	15.7 10.8	Giant	Warfarin Aspirin
			6.5
10	F	Unknown	10.1	LMCA-LAD RCA	LMCA 7.2 RCA 5.8	Fusiform	DAPT
11	F	2.5	3.9	RCA	Proximal 6.5 Mid 9.6	Giant	Aspirin Warfarin

KD: Kawasaki disease; M: male; F: female; LAD: left anterior descending artery; DAPT: dual antiplatelet therapy; RCA: right coronary artery; LCx: left circumflex artery; LMCA: left main coronary artery.